Race Oncology Ltd (ASX:RAC) has been granted a trading halt by the ASX this morning, pending details in relation to regulatory developments in the UK.
Race’s business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma.
The company’s first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies.
The halt will remain in place until the opening of trade on Friday 22 June 2018, or earlier if an announcement is made to the market.